Brow Lift France
Brow Lift in France section, includes general infrmation about Brow Lift Procedure, Brow Lift France Local News, Brow Lift France Surgeon Locator and other Brow Lift related material.
France Brow Lift - The Procedure
With age the brows drop below the eye line and wrinkles appear on the forehead, those make us look angry, sad and tired all times. Brow lift is most popular among ages 40-60 and you can combine it with a facelift or eyelid surgery.
Using the classic technique, the surgeon cuts ear to ear through the scalp behind the hairline. This allows him to get access to the forehead, release the muscles, removes extra skin and lift the eyebrows to higher position. This method is modified for people with high forehead and retreat in the hairline. Then the cut is made in front of the hairline so that brow lift doesn't cause additional retreat.
In the endoscopic approach 3-5 small incisions made on the scalp from ear to ear behind the hairline. Then using special tool extra skin and tissue being removed from the forehead and sometimes attached to the scalp from the inside. With time the wrinkles disappear. Sometimes the surgeon inserts special hook through the endoscop which attaches the tissue to the desired location. The hooks melt with time and the forehead reshapes. In another technique smaller cut is made through the temple areas, the extra skin is removed as described. This approach used when the outer portion of the brows needs to be lift. The operation can be done using local anesthetics with deep sedation.
France Brow Lift - Risks
Every operation has its complications. This one includes damage to the forehead nerves that will result in inability to move the forehead or brows. Lost sensation, usually temporarily, around the scar. Hair loss in the scar margins and wider scar. Infection and bleeding. Endoscopic complications can force the surgeon to do the open surgery, which has longer recovery period.
France Brow Lift - After Surgery
After the surgery with classic approach there might be uncomfortable felling of ant crawling and pain around the scar. Those usually disappear with time and the pain can be managed with painkillers. It may be difficult to open the eyes due to eyelid swallowing. The endoscopic approach has less pain and alter sensation.
France Brow Lift - Healing
You can return to work 10-14 days after the surgery but the final results can be seen only after a few weeks. You must avoid vigorous activities that can elevate your blood pressure for a few weeks. Also avoid prolonged heat or sun exposure. Most marks of the surgery resolve after 3 weeks, minimal swallowing and small hemorrhages can be covered with make up.
Other Brow Lift Procedures
All Face Procedures
Brow Lift France (current)
Brow Lift France BOTOX® Cosmetic
Brow Lift France Ear Surgery
Brow Lift France Facelift
Brow Lift France Neck Lift
More France info...
France Cities with the largest number of visible Roman monuments:
Orange - Arles - N?mes - Elne - Poitiers.
France Cities with an outstanding Gothic cathedral:
Paris - Amiens - Reims - Chartres - Rouen - Beauvais - Laon - Le Mans - Coutances - Bourges-Bordeaux-
Plastic Surgery News...
- New 'Miracle' Skin Healing Cream Now Available to the PublicThe wait is finally over as five of the UK's leading plastic surgeons launch HEAL: a revolutionary new healing gel originally created to soothe and reduce inflammation of the skin following surgery (thereby shortening recover
- This review examines the evidence on rivaroxaban (Xarelto®), an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery of the lower limbs. A licence application was submitted to the EMEA in November 2007.
The review notes that limited data from the phase III RECORD studies (available in abstract form only) suggest that:
• Daily oral rivaroxaban 10mg is statistically significantly more effective than subcutaneous (s.c.) enoxaparin 40mg for short term thromboprophylaxis in patients undergoing total knee replacement; the primary endpoint (composite of DVT, non-fatal PE , and all-cause mortality) occurred in 9.6% and 18.9% of patients assigned to rivaroxaban or enoxaparin, respectively (p < 0.001).
• In extended thromboprophylaxis for hip arthroplasty, the same primary endpoint was achieved in 1.1% of rivaroxaban patients vs. 3.7% of those receiving enoxaparin (p < 0.001).
• Rivaroxaban and enoxaparin recipients experienced a similar incidence of major bleeding events, ranging from 0.1% to 0.6%.
No phase III liver function test data are available, but phase II data suggest that increases in liver enzymes seen in rivaroxaban recipients were of a similar order to enoxaparin recipients after 5–9 days of treatment. However caution is required until further information is available regarding safety. The review concludes “should efficacy and safety data prove favourable for oral rivoroxaban, and depending on cost, the drug might be particularly appropriate for those patients undergoing extended thromboprophylaxis after hip surgery. There will be no necessity to monitor patients for heparin-induced thrombocytopenia and a reduction in at home nurse visits may be possible. Hence, staff capacity may be released. Economic decisions concerning rivaroxaban uptake will need to balance the possible increase in drug costs versus the possible benefits that may accrue.”